Paper48833
Plasma exchange in the management of homozygous familial hypercholesterolaemia.
Thompson GR and 2 others. Lancet, 1975. Cited by 330 papers, by iCite.
Cite this record
ConductScience Library. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Papers, record 48833. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/48833
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hyperlipidemias | Major topic |
| Plasmapheresis | Major topic |
| Adult | |
| Aortic Diseases | |
| Arteriosclerosis | |
| Cholesterol | |
| Cholestyramine Resin | |
| Clofibrate | |
| Coronary Disease | |
| Female | |
| Homozygote | |
| Humans | |
| Lipoproteins, HDL | |
| Lipoproteins, LDL | |
| Nicotinic Acids |
Source PubMed
Cited by51
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 330 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42798794 | Is FH a curable disease? | Glob Cardiol Sci Pract | 2026 | https://conductscience.org/library/papers/42798794 | PubMed |
| 42796005 | Real-World Outcomes of Lipoprotein Apheresis in Homozygous Familial Hypercholesterolemia: A Single-Center Longitudinal Experience. | J Clin Med | 2026 | https://conductscience.org/library/papers/42796005 | PubMed |
| 41998231 | 50 years of apheresis for homozygous familial hypercholesterolemia. | Nat Cardiovasc Res | 2026 | https://conductscience.org/library/papers/41998231 | PubMed |
| 41369603 | Therapeutic Plasma Exchange and Evinacumab for Homozygous Familial Hypercholesterolemia. | JACC Case Rep | 2026 | https://conductscience.org/library/papers/41369603 | PubMed |
| 38541699 | Novel Therapeutic Approaches for the Management of Elevated Lipoprotein(a): From Traditional Agents to Future Treatment Options. | Life (Basel) | 2024 | https://conductscience.org/library/papers/38541699 | PubMed |
| 37273067 | Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a). | Curr Atheroscler Rep | 2023 | https://conductscience.org/library/papers/37273067 | PubMed |
| 36701088 | Apheresis: What Should a Clinician Know? | Curr Atheroscler Rep | 2023 | https://conductscience.org/library/papers/36701088 | PubMed |
| 36682773 | Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022. | J Atheroscler Thromb | 2023 | https://conductscience.org/library/papers/36682773 | PubMed |
| 35303294 | Contemporary Management of Dyslipidemia. | Drugs | 2022 | https://conductscience.org/library/papers/35303294 | PubMed |
| 34759397 | Extracorporeal Therapy in Dermatology. | Indian J Dermatol | 2021 | https://conductscience.org/library/papers/34759397 | PubMed |
| 32651185 | FH through the retrospectoscope. | J Lipid Res | 2021 | https://conductscience.org/library/papers/32651185 | PubMed |
| 31041550 | Current Role of Lipoprotein Apheresis. | Curr Atheroscler Rep | 2019 | https://conductscience.org/library/papers/31041550 | PubMed |
| 30050433 | Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. | Front Pharmacol | 2018 | https://conductscience.org/library/papers/30050433 | PubMed |
| 29877295 | Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. | J Atheroscler Thromb | 2018 | https://conductscience.org/library/papers/29877295 | PubMed |
| 28185213 | Hyperlipoproteinaemia(a) - apheresis and emerging therapies. | Clin Res Cardiol Suppl | 2017 | https://conductscience.org/library/papers/28185213 | PubMed |
| 27416572 | The Italian Consensus Conferences on low density lipoprotein-cholesterol apheresis. | Blood Transfus | 2017 | https://conductscience.org/library/papers/27416572 | PubMed |
| 26889050 | Lipoprotein apheresis to treat elevated lipoprotein (a). | J Lipid Res | 2016 | https://conductscience.org/library/papers/26889050 | PubMed |
| 26201613 | Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment. | Wien Klin Wochenschr | 2015 | https://conductscience.org/library/papers/26201613 | PubMed |
| 26004920 | Lipoprotein apheresis. | Curr Atheroscler Rep | 2015 | https://conductscience.org/library/papers/26004920 | PubMed |
| 25670911 | The genetics of familial hypercholesterolemia and emerging therapies. | Appl Clin Genet | 2015 | https://conductscience.org/library/papers/25670911 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/48833
GET https://conductscience.org/api/papers/v1/48833/cited_by?page=2